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Purpose: Noninvasive prenatal screening (NIPS) using cell-free
DNA in maternal blood is highly sensitive for detecting fetal
trisomies 21, 18, and 13. Using a genome-wide approach, other
chromosome anomalies can also be detected. We report on the
origin, frequency, and clinical significance of these other chromo-
some aberrations found in pregnancies at risk for trisomy 21,
18, or 13.
Methods: Whole-genome shallow massively parallel sequencing
was used and all autosomes were analyzed.
Results: In 78 of 2,527 cases (3.1%) NIPS was indicative of
trisomy 21, 18, or 13, and in 41 (1.6%) of other chromosome
aberrations. The latter were of fetal (n = 10), placental (n = 22),
maternal (n = 1) or unknown (n = 7). One case lacked cytogenetic
follow-up. Nine of the 10 fetal cases were associated with an
abnormal phenotype. Thirteen of the 22 (59%) placental aberra-
tions were associated with fetal congenital anomalies and/or poor
fetal growth (op10), which was severe (op2.3) in six cases.
Conclusion: Genome-wide NIPS in pregnancies at risk for trisomy
21, 18, or 13, reveals a chromosomal aberration other than trisomy
21, 18 or 13 in about one-third of the abnormal cases. The majority
involves a fetal or placental chromosome aberration with clinical
relevance for pregnancy management.
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INTRODUCTION
Noninvasive prenatal screening (NIPS) is a test based on the
analysis of cell-free DNA in blood of pregnant women. It is a
safe and reliable method to screen for trisomies 21, 18, and
13,1 both in high- and low-risk pregnancies.2 NIPS may also
reveal other chromosome aberrations.3 Both the origin of the
cell-free DNA as well as the combination of sequencing
technique and bioinformatical analysis will determine the
types and size of detectable chromosome aberrations.4 When
whole-genome sequencing and analysis are performed, other
fetal chromosome aberrations than the common aneuploidies
can be detected.5,6 Since the majority of cell-free DNA is of
maternal origin, maternal copy-number variants (CNVs) and
chromosome anomalies due to a maternal malignancy can
also be detected, possibly leading to false-positive NIPS
results.3,7–9 Moreover, NIPS can reveal chromosomal anoma-
lies limited to the placenta (not present in the fetus), because
the so-called cell-free DNA fetal fraction, about 10% at
10 weeks of gestation,10 is derived from the placental
cytotrophoblast.11–13 Therefore, to confirm that a chromoso-
mal anomaly detected with NIPS is fetal, diagnostic testing is
necessary. In rare cases NIPS will not detect a trisomy,
because it is present in the fetus but not in the placenta.14
In the Netherlands, screening for untreatable disorders is
subject to a Ministerial License. As from 1 April 2014, the
eight Dutch University Medical Centers received a license to
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offer NIPS as an alternative option to invasive testing in
patients at elevated risk for trisomy 21, 18, or 13. The project
was called the TRIDENT study (Trial by Dutch laboratories
for Evaluation of Non-Invasive Prenatal Testing), and overall
data for the first 5 months have been published.15,16 Here we
present the chromosome aberrations other than trisomy 21,
18 and 13 that were detected during the first year of
TRIDENT. Clinical outcomes as well as cytogenetic follow-up
studies during and after pregnancy are available for almost all
these pregnancies.
MATERIALS AND METHODS
Study population and sample collection
Between 1 April 2014 and 1 April 2015, 3,306 high-risk
pregnant women chose NIPS as opposed to diagnostic
(invasive) testing or no testing. Women had access to these
choices when their risk for a fetus with trisomy 21, 18, or 13
was ≥ 1:200 based on first trimester combined test results or
because of medical history (previous child with a trisomy or
parental carriership of a Robertsonian translocation involving
chromosome 13 or 21). Exclusion criteria included vanishing
twins and are described in more detail in Oepkes et al.15 All
women signed an informed consent. A license for the study
was granted by the Minister of Health (11016-118701-PG).
The license did not allow analysis of the sex chromosomes.
The study was approved by the local University Medical
Center Ethics Committees.
The cohort in the present study partially overlaps with the
cohort previously described, which reported on the common
trisomies.15
Massively parallel shotgun sequencing and analysis
Whole-genome shallow massively parallel shotgun sequen-
cing was performed in all cases as described previously.15 A
minimum of 5 million mapped reads was set, but most cases
were sequenced at a depth of 10–12 million reads. In 753 of
3,306 cases (data from two centers) only the z-scores of
chromosomes 21, 18, and 13 were determined. In all other
cases (2,553/3,306), WISECONDOR was used for analyzing
the whole genome with a resolution of approximately 10–
15Mb at the sequencing depth used.15,17 The z-score cut-off
that was employed for calling trisomies and subchromosomal
aberrations based on the sliding window approach was 3. For
calling trisomies an additional threshold was used that at least
50% of all bins on a chromosome should be called. For each
sample a WISECONDOR output plot was produced and
visually inspected as has been described.17 The results of these
2,553 cases are presented here.
Follow-up pre- and postnatal cytogenetic studies
In case of an abnormal NIPS result, parents were counseled by
a clinical geneticist and informed consent was obtained for
follow-up testing. Depending on the type of chromosomal
aberration, maternal DNA was tested with array (Infinium_
CytoSNP_850K genotyping array, Illumina Inc., San Diego,
CA, USA, CytoScan HD, Affymetrix, Inc, Santa Clara, CA,
USA or 180k oligo-array, Agilent, Santa Clara, CA, USA) and/
or invasive testing (chorionic villus sampling (CVS) or
amniocentesis) was performed. Uniparental disomy studies
were performed by single-nucleotide polymorphism array
(Illumina or Affymetrix; see above) or by polymorphic
microsatellite repeat analysis, in cases of trisomy 6, 7, 11,
14, 15, 16, and 20.
Routine methods were used for prenatal cytogenetic investi-
gations. Chorionic villi were investigated with array using
DNA isolated from cytotrophoblast and mesenchymal core
separately.18 Uncultured amniotic fluid cells (AF) cells were
investigated with fluorescent in situ hybridization or array, and
cultured cells with conventional karyotyping, fluorescent in situ
hybridization, or array. Chromosomal mosaicism was investi-
gated according to the European Cytogenetic Guidelines.19
In cases of suspected confined placental mosaicism (CPM)
postnatal cytogenetic studies of the placenta were performed.
One to five chorionic villi biopsies from different quadrants of
the placenta were analyzed by karyotyping, fluorescent in situ
hybridization, quantitative fluorescence polymerase chain reac-
tion (Devyser compact v3 QF-PCR, Devyser, Hägersten,
Sweden; Aneufast v3.0, Nijmegen, Genomed Ltd, Kent, UK;
or QSTRplus v2, Elucigene, Manchester, UK), or array. Both
cytotrophoblast and mesenchymal core were investigated in
most cases.18 If parents refrained from invasive testing, newborn
cord blood and/or a skin biopsy was available in most cases.
Classification of abnormal findings
Abnormal findings other than trisomy 21, 18, or 13 were
classified into four categories:
1. Fetal aberrations: chromosome aberration confirmed in
AF, cord blood, or skin.
2. Placental aberrations: chromosome aberrations confirmed
in first trimester chorionic villi or postnatal placenta but
absent in AF/cord blood/postnatal tissue, or chromosome
anomalies typically involved in CPM, but with no or
insufficient placental tissues available for cytogenetic confir-
mation. This was based on large chorionic villi cytogenetic
studies showing that trisomies such as trisomy 3, 7, 8, 9, 16,
and 20 are rarely confirmed in the fetus.12,20–23 If in such a
case only 1 or 2 placenta biopsies were available and these
were normal, a placental aberration was considered not to
be excluded due to placental site variation.24
3. Maternal CNV: a CNV that is confirmed with array on
maternal DNA. A maternal CNV can be inferred from
the WISECONDOR results when a small gain or loss
with a respectively very high or low z-score is restricted
to a small part of a chromosome.
4. Unresolved: classification not possible despite pre- and
postnatal cytogenetic follow-up investigations.
Follow-up clinical studies
In most cases, a fetal anatomy scan was performed around
20 weeks of gestation as part of standard screening, and when
Aberrations other than common trisomies detected by NIPS | VAN OPSTAL et al ORIGINAL RESEARCH ARTICLE
GENETICS in MEDICINE | Volume 20 | Number 5 | May 2018 481
CPM was suspected, scans were repeated in the second and
third trimester to monitor fetal growth. Postnatally, clinical
follow-up was collected. Intrauterine growth restriction
(IUGR) was defined as a birthweight-for-gestational age
below the 2.3th percentile (op2.3) and small for gestational
age (SGA) as birthweight below the 10th percentile (op10).25
RESULTS
In 2,527 of 2,553 (99%) cases, results of genome-wide analysis
were reported. In 78 (3.1%) cases a common trisomy was
found (trisomy 21 (n = 61), trisomy 18 (n = 11), and
trisomy 13 (n = 6)). In 41 (1.6%) cases another chromosome
aberration was involved. In one case of trisomy 8, the
pregnancy was terminated in a private clinic before follow-up
testing could be performed. In the other 40 cases, follow-up
was available. A fetal origin of the chromosome aberration
was identified in 10 cases (25%), a placental origin in 22 cases
(55%), and a maternal origin in 1 case (2%). In 7 cases (18%)
the origin remained unknown.
An overview of all 41 cases with a chromosome aberration
other than trisomy 21, 18, and 13, their origin, and pregnancy
outcome is provided in Figure 1.
In 10/40 (25%) cases the chromosome aberration was
shown to be fetal (Table 1 and Supplementary Table S1
online). After confirmation, five pregnancies were terminated
and one case ended in an intrauterine death (case 1.5, Table 1
and Supplementary Table S1). Four pregnancies resulted in
live births, but three of the infants had multiple congenital
anomalies (MCA). The fourth case (case 1.3, Table 1 and
Supplementary Table S1) had trisomy 15 mosaicism in
uncultured but not in cultured amniotic fluid cells. This child
developed normally up to the last examination at 11 months
of age. For details about cytogenetic and clinical follow-up, see
Supplementary Table S1.
In 22/40 (55%) cases CPM was most likely (Table 2 and
Supplementary Table S2 online). Trisomy 7 and trisomy 16
were most commonly involved. Table 2 summarizes the
clinical outcome per chromosome aberration. In all but one
case of trisomy 2, the pregnancy ended with live birth. MCA
were detected in 5/22 (23%) cases (cases 2.1, 2.8, 2.15, 2.16,
and 2.19, Supplementary Table S2). Despite normal
cytogenetic results in amniotic fluid and/or cord blood, an
association with the trisomy and/or uniparental disomy
cannot be excluded in four of five cases. In case 2.15,
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Figure 1 The origin of chromosome aberrations other than the common trisomies and pregnancy outcome. AGA, appropriate growth for
gestational age; CNV, copy-number variation; DD, developmental delay; FU, follow-up investigations; IUD, intrauterine death; IUGR, intrauterine growth
restriction (op2.3); MCA, multiple congenital anomalies; NIPS, noninvasive prenatal screening; SGA, small for gestational age (op10); TOP, termination
of pregnancy.
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hypomethylation of the H19 differentially methylated region
allowed to make the diagnosis of Silver–Russell syndrome.
IUGR (op2.3) was found in 6/22 (27%) cases: two cases with
MCA (2.1 and 2.16, Supplementary Table S2) and four cases
with isolated IUGR (2.2, 2.6, 2.11, 2.14, Supplementary Table
S2). In 7/22 (32%) other cases, SGA (birth weight between
p2.3 and p10) was found: three cases with MCA (2.8, 2.15,
and 2.19, Supplementary Table S2) and four cases with SGA
only (2.13, 2.17, 2.20, and 2.21, Supplementary Table S2). In
only 9/22 (41%) cases, the pregnancy was uneventful. Details
about the cytogenetic and clinical follow-up studies are shown
in Supplementary Table S2.
Maternal CNVs were commonly detected, but most were of
benign nature or at the most of unknown clinical significance.
Eight such CNVs were reported in the initial phase of the
study but with current experience would not be reported
anymore, and therefore are not included in the analysis. Only
one, a 1.4-Mb duplication on chromosome 17p, associated
with Charcot–Marie–Tooth (CMT1A), was disclosed because
of its clinical relevance. The mother was already known to be
clinically affected and did not opt for invasive testing.
Finally, in 7/40 (18%) cases, the origin of the abnormal NIPS
result could not be determined despite clinical and cytogenetic
follow-up investigations (Supplementary Table S3 online).
DISCUSSION
Our data show that when genome-wide NIPS is used in
pregnant women tested because of an increased risk for one of
the common aneuploidies, one-third of the chromosome
aberrations are different from trisomy 21, 18, or 13. Genetic
follow-up testing confirmed a fetal, placental, or maternal
origin of the chromosome aberration in respectively 25%,
55%, and 2% of the abnormal cases. The present study is
unique in that near complete (98%) clinical and cytogenetic
follow-up was achieved. Especially placental analyses, which
usually are not performed,26 allowed us to confirm the large
contribution of CPM to abnormal NIPS findings other than
trisomy 21, 18, and 13. The frequency of pathogenic maternal
CNVs in our series (0.04%, 1/2,553) is comparable to that
reported by Brison et al.8 (0.05%, 5/9,882). It is to be expected
that in a general obstetric population the relative proportions
of the different categories of chromosome aberrations, as
shown in this paper, will be different with an expected
decrease of common trisomies3 as well as of CPM, which is
associated with abnormal first trimester combined test results.
Table 1 Fetal chromosome aberrations
Case NIPS result Follow-up during pregnancy Follow-up after birth
Cytogenetic testing Ultrasound anomalies Cytogenetic testing Pregnancy outcome
AF Cord blood/skin Placenta
1.1 tris 9 — Yes mos +9 — Liveborn with MCA
1.2 tris 9 mos +9 Yes mos +9 — Liveborn with MCA
1.3 tris 15,22 mos +15 No — mos +15 Liveborn, no MCA
1.4 tris 22 mos +22 — — — TOP, MCA
1.5 dup 2p Unbalanced translocation der(9)t(2;9)
(p21;p24)
Yes — — IUD at 30 wks
1.6 del 6q — No del(6)(q14.1q16.1) — Liveborn with MCA
1.7 del 8p/dup 8q mos +8,del(8) No — — TOP, MCA
1.8 del 9p del(9)(p24.3p24.1) and dup(9)(p24.1p23) No — — TOP, no autopsy
1.9 del 12q del(12)(q21.2q21.33) No — — TOP, no MCA
1.10 del 18p Unbalanced translocation der(13;18)
(q10;q10)
— — — TOP, dysmorphic features
—, not performed; AF, amniotic fluid; del, deletion; dup, duplication; IUD, intrauterine fetal death; MCA, multiple congenital malformations; mos, mosaicism; NIPS, non-
invasive prenatal screening; TOP, termination of pregnancy; tris, trisomy.
Table 2 Placental chromosome aberrations
Number of cases NIPS result Pregnancy outcome
1 tris 2 TOP with MCA and IUGR
1 tris 3 Liveborn, IUGR
6 tris 7 6× Liveborn
1× IUGR
1× SGA + MCA
4× AGA
2 tris 8 2× Liveborn, AGA
1 tris 9 Liveborn, IUGR
9 tris 16 9× Liveborn:
1× IUGR + MCA
1× IUGR
2× SGA + MCA
3× SGA
2× AGA
1 tris 22 Liveborn, SGA
1 tris 2 and 20 Liveborn, AGA
AGA, appropriate growth for gestational age; IUGR, intrauterine growth restric-
tion, op2.3; MCA, multiple congenital malformations; NIPS, noninvasive prenatal
screening; SGA, small for gestational age, op10; tris, trisomy; TOP, termination
of pregnancy.
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All women had received pretest counseling on possible
findings with genome-wide NIPS. When an aberration other
than the common trisomies was detected this result was
disclosed. In 25% of the cases, diagnostic follow-up testing
showed the chromosome aberration to be fetal. All these fetal
chromosome anomalies were known to be associated with
developmental delay and/or MCA. One case with trisomy 15
mosaicism developed normally up to the age of 11 months. In
55% of the cases CPM was involved, and our data on
postnatal outcome confirm the association with an increased
risk for fetal developmental and growth problems.27–29 It is to
be expected that the adverse pregnancy outcome in several
cases of suspected CPM is caused by occult fetal mosaicism.30
Therefore, it is important that clinicians are aware that the
term CPM can be misleading since strict confinement to the
placenta can never be proven. Other possible explanations for
fetal pathology in case of a placental trisomy are uniparental
disomy of an imprinted chromosome, or uniparental disomy
leading to homozygosity for a recessive disease allele.31 In one
case a maternal pathogenic CNV was found of which the fetus
potentially was a carrier. Finally, in 18% of the cases follow-up
cytogenetic studies did not reveal the chromosome aberration
and therefore their origin remains unknown. An unnoticed
vanishing twin, low-grade chromosomal mosaicism, or other
biological factors such as sample quality can be responsible
for these false-positive results. Because these data show a
significant risk for obstetric pathology and fetal anomalies, we
advise close obstetric surveillance in all cases of abnormal
NIPS results other than the common trisomies, even if the
fetal karyotype as determined by diagnostic testing is normal.
We have shown that in an elevated risk population,
genome-wide NIPS may detect a range of clinically relevant
chromosome anomalies. Questionnaire studies showed that
most Dutch pregnant women and health-care providers
support testing for a wider range of severe disorders.32,33
Recently, the American College of Medical Genetics and
Genomics did not recommend to screen for autosomal
aneuploidies other than those involving chromosomes 21,
18 and 13 nor for genome-wide CNVs.34 It is argued that the
former chromosome aberrations are rare, that they may lead
to unnecessary diagnostic procedures and even unnecessary
pregnancy terminations, and that counseling is challenging.34
As to the frequency, in the present study the rare fetal
chromosome anomalies as a group were more frequent than
trisomy 13 and almost as frequent as trisomy 18, confirming
previous studies.35 All fetal chromosome aberrations but
one were severe and relevant for the parents to know. Five
couples chose to terminate the pregnancy; in one case the
fetus died in utero. Genome-wide NIPS indeed led to 29
(1.1%) extra invasive procedures but also to an increased
prenatal detection of true fetal chromosome aberrations that
otherwise potentially would have remained undetected: in
more than half of the cases with a fetal chromosome
aberration in which ultrasound investigations were per-
formed, the 20-week anatomy scan was normal and therefore
falsely reassuring. Moreover, with a targeted analysis not all
invasive tests would have been avoided since unusual placental
aneuploidies2,36,37 as well as benign maternal CNVs, present in
~ 0.1% of pregnancies (45/51,000),38 may lead to test failures or
false-positive results for chromosomes 21, 18, or 13, requiring
invasive testing as well for a definitive diagnosis.
Pregnancy termination without confirmatory testing
occurred once. In most cases this can be prevented by
adequate pre- and posttest counseling emphasizing the
importance of confirmatory testing. NIPS posttest counseling
is challenging but, due to the origin of the cell-free DNA fetal
fraction, the NIPS result in fact resembles the cytogenetic
result of direct or short-term culture villi. Therefore, for
counseling about the clinical significance of an abnormal
NIPS result and about the most appropriate diagnostic test,
the clinician can use data from a large number of studies on
cytogenetic analysis in short- and long-term cultured
villi.21–23,28,39,40 Apart from factors such as gestational age
and patient preferences, the choice for CVS or amniocentesis
will largely depend on the type of chromosome aberration
involved.21 We realize that access to appropriately trained
genetic counselors and clinical geneticists differs worldwide
and therefore national recommendations will be needed in
addition to society guidelines.
In conclusion, about one-third of all chromosome aberra-
tions found with NIPS in pregnant women at increased risk
for the common aneuploidies is different from trisomy 21, 18,
and 13. This study revealed their origin to be fetal or placental
in ~ 80% of the cases. Fetal as well as placental chromosome
anomalies were associated with MCA in the fetus/child and/or
impaired fetal growth. It can therefore be concluded that
findings other than the common trisomies are clinically
relevant for pregnancy management, and that there is
potential clinical utility in performing genome-wide NIPS.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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